he lower chamber is expected to vote on legislation that would permanently repeal Medicare's sustainable growth-rate formula for physician payment, which might also include a provision to either repeal or delay the ACA's individual insurance mandate as a way to pay for the SGR fix.
House Republicans have found another back-door way to attempt a partial dismantling of the Affordable Care Act. The lower chamber is expected to vote on legislation that would permanently repeal Medicare's sustainable growth-rate formula for physician payment, which might also include a provision to either repeal or delay the ACA's individual insurance mandate as a way to pay for the SGR fix. But as before, their efforts are certain to die in the Senate, making another temporary, not a permanent, SGR fix more likely as a March 31 deadline looms.
The House is likely to vote this week on the SGR Repeal and Medicare Provider and Payment Modernization Act of 2014, but it remains unclear if the GOP lawmakers will attach a provision to repeal the individual mandate or delay it by several years, as one news report suggested. According to the Congressional Budget Office, a one-year delay of the individual mandate would save about $9 billion over 10 years. A permanent repeal of Medicare's SGR would cost about $138 billion over 10 years.
Julius Hobson, a senior policy adviser at the law firm Polsinelli and former lobbyist for the American Medical Association, said this approach is not likely the path to solving the SGR problem.
Read the full story here: http://bit.ly/NRztmT
Source: Modern Healthcare
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More